Core Insights - Veeva Systems has launched Veeva CRM Pulse, a data subscription service that provides quarterly healthcare professional (HCP) access and multichannel engagement metrics for the life sciences industry [1][2] - The service aims to enhance segmentation, targeting, and engagement planning for commercial operations and data analytics teams [1][2] Product Details - Veeva CRM Pulse is derived from over 500 million Veeva CRM interactions, making it a comprehensive source of HCP access data [1] - The product is currently available for Veeva's CRM customers, with 2024 quarterly data covering multiple countries including the United States, Canada, and several European nations [2] - Quarterly data releases for 2025 are set to begin in April, with plans to expand availability to additional countries in Asia and Europe next year [2] Company Overview - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers ranging from large biopharmaceutical companies to emerging biotechs [4] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders, including customers and shareholders [4]

Core Viewpoint - Veeva Systems Inc. has introduced the Direct Data API as part of the Veeva Vault Platform, which is expected to enhance AI innovation in the life sciences sector [1][5][6]. Company Developments - The Direct Data API allows for faster access to Veeva Vault data, making it more appealing to the life sciences industry and potentially boosting Veeva's overall business [2][5]. - Veeva Systems currently has a market capitalization of $36.39 billion and an earnings yield of 3.1%, which is favorable compared to the industry's negative yield [4]. - The company reported an earnings surprise of 10.8% in the last quarter [4]. - The Direct Data API will include connectors for platforms like Amazon Redshift, Snowflake, Databricks, and Power BI later this year, facilitating AI applications and analytics [5][6]. Stock Performance - Following the announcement of the Direct Data API, Veeva's shares declined by nearly 3.6% [3]. - Over the past year, Veeva's shares have decreased by 1.2%, while the industry has seen an 11.3% decline and the S&P 500 has gained 16.2% [12]. Industry Prospects - The global AI in life sciences market is projected to grow from $2.73 billion in 2025 to $13.89 billion by 2034, with a compound annual growth rate (CAGR) of approximately 19.8% [7]. - The demand for therapeutics and the need for improved productivity are key factors driving this market growth [7][8].

Core Insights - Veeva Systems has launched Veeva Commercial Pulse, a data subscription service providing quarterly healthcare professional (HCP) access and multichannel engagement metrics for the life sciences industry [1][2] - The service aims to enhance segmentation, targeting, and engagement planning for commercial operations and data analytics teams [1][2] - Veeva Commercial Pulse is part of the broader Veeva Data Cloud ecosystem, which includes other products like Veeva OpenData, Veeva Link, and Veeva Compass [3] Product Features - Commercial Pulse offers unique HCP data that is derived from over 500 million Veeva CRM interactions, making it one of the most complete and accurate datasets for HCP access [1][6] - The data covers more than three million HCPs across 102 specialties and 21 countries, providing unmatched coverage for access and engagement metrics [6] - The initial data release includes 2024 quarterly data for multiple countries, with plans to expand to additional countries in Asia and Europe next year [2] Company Background - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [4] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders, including customers, employees, and shareholders [4]

Core Insights - Veeva Systems has announced that 6 of the top 20 biopharmaceutical companies have selected Veeva China CRM Suite to enhance healthcare professional engagement in China [1] - Veeva China CRM Suite is tailored specifically for the Chinese market, incorporating local compliance and quality standards, and is hosted within the country [1][2] - The suite is part of Veeva Commercial Cloud, which provides a comprehensive technology foundation for commercial excellence, including various China-specific applications [2] Company Overview - Veeva Systems is recognized as the global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical firms and emerging biotech companies [3] - The company emphasizes innovation, product excellence, and customer success, while also being committed to balancing the interests of all stakeholders [3]

Core Viewpoint - Veeva Systems (VEEV) is expected to report quarterly earnings of $1.58 per share, a 14.5% increase year-over-year, with revenues projected at $698.28 million, reflecting a 10.7% increase compared to the same period last year [1] Earnings Estimates - There has been no revision in the consensus EPS estimate for the quarter over the past 30 days, indicating that analysts have not changed their initial projections [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenues- Subscription services' to reach $595.93 million, indicating a year-over-year increase of 14.3% [5] - 'Revenues- Professional services and other' are expected to be $102.35 million, suggesting a decline of 6.2% year-over-year [5] - 'Revenues- Professional services and other- Veeva R&D Solutions' is projected at $59.40 million, reflecting a decrease of 6% from the previous year [6] - 'Revenues- Subscription services- Veeva R&D Solutions' is expected to be $312.72 million, indicating a year-over-year increase of 20.5% [6] - 'Revenues- Subscription services- Veeva Commercial Solutions' is forecasted to reach $283.40 million, showing an 8.2% increase from the prior year [7] - 'Revenues- Professional services and other- Veeva Commercial Solutions' is estimated at $42.85 million, indicating a year-over-year decline of 6.7% [7] Gross Margin Estimates - 'Non-GAAP Gross Margin- Professional Services and other' is expected to be 22.9%, down from 23.9% a year ago [8] - 'Non-GAAP Gross Margin- Subscription services' is projected to remain at 85.7%, unchanged from the previous year [8] Stock Performance - Veeva shares have shown a return of -6.8% over the past month, compared to a -2.4% change in the Zacks S&P 500 composite [9] - With a Zacks Rank 3 (Hold), VEEV is anticipated to perform in line with the overall market in the near future [9]

Core Insights - Veeva Systems has introduced the Direct Data API, which allows access to Veeva Vault data up to 100 times faster than traditional APIs, included at no additional license fee [1][2][3] - The Direct Data API is designed to support AI applications, analytics, and system integrations, with future connectors planned for platforms like Amazon Redshift, Snowflake, Databricks, and Power BI [2][3] - This technology is part of Veeva's strategy to enhance automation and AI capabilities in the life sciences sector, with ongoing development of AI solutions such as TMF Bot and Vault CRM Bot [3][4] Company Overview - Veeva Systems is a leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [4] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders as a Public Benefit Corporation [4]

Core Viewpoint - Veeva Systems will announce its financial results for the fourth quarter and full fiscal year on March 5, 2025, after market close, followed by a conference call to discuss the results [1][2]. Company Overview - Veeva Systems is a global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs [3]. - The company is committed to innovation, product excellence, and customer success, while also balancing the interests of all stakeholders as a Public Benefit Corporation [3]. Investor Relations - Veeva will post prepared remarks on its investor relations website prior to the conference call, and a replay of the webcast will be available afterward [2][4]. - The company uses its investor relations website to disclose material non-public information and comply with disclosure obligations under Regulation FD [4].

Core Insights - Veeva Systems announced that Servier will adopt Veeva RIM to unify its global regulatory operations, enhancing visibility, submission speed, and compliance [1][2] - The implementation of Veeva RIM will streamline Servier's operations and accelerate patient access to new medicines, allowing for quick adaptation to evolving EU regulatory demands [2][3] - Veeva RIM is part of Veeva Development Cloud, which supports product development across clinical, regulatory, quality, and safety domains [3] Company Overview - Servier is an independent global pharmaceutical leader based in France, focusing on cardio-metabolism, venous diseases, and oncology therapies [2] - Veeva Systems is a global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [4]

Core Insights - Veeva Systems announced that over 200 companies, including 17 of the top 20 biopharmas, utilize Veeva CTMS to enhance trial efficiency and collaboration [1] - The increasing complexity of studies and data volumes has led biopharmas and CROs to centralize data and documents with Veeva CTMS, streamlining processes [1][2] - Veeva CTMS allows clinical teams to proactively manage studies, quickly identify issues, and maintain compliance with global regulations [2][3] Company Overview - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, from large biopharmaceutical companies to emerging biotechs [4] - The company is committed to innovation, product excellence, and customer success, balancing the interests of all stakeholders [4] Product Innovations - Veeva continues to deliver clinical innovations to help biopharmas adapt to changes in trial operating models and evolving regulations [3] - New advancements in Veeva CTMS include capabilities that support both insourced and outsourced operating models, with three product releases per year to enhance flexibility [3][6] - Features such as automated data transfers from CROs to sponsors and oversight issue tracking are designed to improve visibility and speed in trial management [6]

Veeva Systems Inc. (VEEV) , on Thursday, announced a product partnership with Zifo. The tie-up aims to help biopharmas modernize quality control (QC) operations.Per Veeva Systems, companies can import data directly from any source document or other LIMS into Veeva LIMS by bringing together Veeva LIMS with Zifo's data integration and management platform, qcKen. This integration will likely simplify master data configuration during LIMS implementation and site deployment, making it easier for companies to adv ...